ABVC BioPharma, Inc. (ABVC) Financial Statements (2024 and earlier)

Company Profile

Business Address 44370 OLD WARM SPRINGS BLVD.
FREMONT, CA 94538
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
9/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1615,9374,27314440205
Cash and cash equivalents 855,8294,27314440205
Short-term investments76108    
Restricted cash and investments 1,306737    
Receivables856283696334402,550
Inventory, net of allowances, customer advances and progress billings  26    
Inventory  26    
Prepaid expense   172770 
Other undisclosed current assets6642,6431,03132316 
Total current assets:2,9879,6256,173878962,755
Noncurrent Assets
Operating lease, right-of-use asset1,1611,4721,773524
Property, plant and equipment574526515521  
Long-term investments and receivables1,9839331,1913,365  
Due from related parties1,141     
Long-term investments8429331,1913,365  
Prepaid expense135119119135  
Deferred income tax assets1179821,791 
Other undisclosed noncurrent assets2,89741461,504  
Total noncurrent assets:6,8684,0735,4346,050  
TOTAL ASSETS:9,85513,69811,6076,928962,755
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,9101,3012368544924
Employee-related liabilities  66144424
Accounts payable   2324  
Accrued liabilities2,9101,301  5 
Deferred revenue    
Debt1,8941,6401,7362,336300 
Due to related parties636393288426250 
Other undisclosed current liabilities3803582,7973,3674,569 
Total current liabilities:5,8203,6924,8446,8145,56824
Noncurrent Liabilities
Long-term debt and lease obligation 1,1253,957236  
Long-term debt, excluding current maturities  2,500   
Liabilities, other than long-term debt792   250 
Due to related parties    250 
Operating lease, liability7921,1251,457236
Other undisclosed noncurrent liabilities8(1,114)(1,313)327 
Total noncurrent liabilities:8001,1354,100238277 
Other undisclosed liabilities      4,124
Total liabilities:6,6194,8288,9457,0535,8464,148
Equity
Equity, attributable to parent, including:3,0998,8443,438(151)(5,749)(1,393)
Common stock33292419214214
Treasury stock, value(9,100)(9,100)(9,100)(9,100)  
Additional paid in capital67,90758,11440,75228,18013,91513,789
Accumulated other comprehensive income517540    
Accumulated deficit(54,904)(38,481)(25,642)(15,851)(19,878)(15,395)
Stockholders' equity note, subscriptions receivable(1,354)(2,257)(3,160)(4,063)  
Other undisclosed equity, attributable to parent   565664  
Equity, attributable to noncontrolling interest13827(776)26  
Total equity:3,2368,8702,662(125)(5,749)(1,393)
TOTAL LIABILITIES AND EQUITY:9,85513,69811,6076,928962,755

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
9/30/2017
Revenues970356483702  
Loss on disposition of assets for financial service operations  (270)(1,169)(210)(2,549)
Cost of revenue(286)(5)(19)(20)(1) 
Cost of goods and services sold     (1) 
Gross profit:683351464682(1) 
Operating expenses(15,798)(12,057)(8,970)(4,140)(1,394)(3,858)
Other undisclosed operating income (loss)     1(138)
Operating loss:(15,114)(11,706)(8,506)(3,459)(1,394)(3,996)
Nonoperating income (expense)(400)495(2,308)(552)(2,706)(75)
Investment income, nonoperating  1355143(0)0
Gain (loss), foreign currency transaction, before tax  426(3)0  
Other nonoperating income (expense)(400)2217593  
Interest and debt expense(294)(227)(405)(1)(156)(75)
Loss from continuing operations before equity method investments, income taxes:(15,809)(11,438)(11,219)(4,011)(4,255)(4,146)
Other undisclosed income from continuing operations before income taxes294227405115675
Loss from continuing operations before income taxes:(15,515)(11,211)(10,814)(4,010)(4,099)(4,071)
Income tax expense (benefit)(798)(825)22077(2)(1)
Loss from continuing operations:(16,312)(12,036)(10,594)(3,933)(4,101)(4,072)
Loss before gain (loss) on sale of properties:(12,036)(10,594)(3,933)(4,101)(4,072)
Net loss:(16,312)(12,036)(10,594)(3,933)(4,101)(4,072)
Net income (loss) attributable to noncontrolling interest(111)12,036    
Other undisclosed net loss attributable to parent  (12,036)    
Net loss attributable to parent:(16,423)(12,036)(10,594)(3,933)(4,101)(4,072)
Other undisclosed net loss available to common stockholders, basic  (803)    
Net loss available to common stockholders, diluted:(16,423)(12,839)(10,594)(3,933)(4,101)(4,072)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
9/30/2017
Net loss:(16,312)(12,036)(10,594)(3,933)(4,101)(4,072)
Comprehensive loss:(16,312)(12,036)(10,594)(3,933)(4,101)(4,072)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(111)12,036    
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(23)(12,864)704299  
Comprehensive loss, net of tax, attributable to parent:(16,446)(12,864)(9,890)(3,634)(4,101)(4,072)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: